Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prof Cameron and Best's group in collaboration with Dr Ghevaert have published a paper in Biomaterials showing platelet production from in vitro derived megakaryocytes. Platelet production has always been the bottle neck in the venture to produce platelets for human use in the laboratory. This paper illustrates a very important step to make this a reality and illustrates a brilliant collaboration across disciplines and groups who are part of the BHF Oxbridge Centre of Regenerative Medicine.

The researchers cultured megakaryocytes from induced stem cells on a specialised growth support within a flow chamber that mimics features of the bone marrow. The system is able to produce an out flow of platelets that can take part in clotting. It is hoped that the system will aid in mass production of in vitro platelets and modified platelets as responsive drug delivery devices. The full paper can be found here.

See also

Shepherd et al, Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity. Biomaterials. 2018.

Moreau et al, Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nat Comms. 2016.

Similar stories

AI analysis of routine heart scans can predict risk of a developing heart problems ten years in advance, new research finds

A research team led by scientists at the Radcliffe Department of Medicine, University of Oxford has developed an Artificial Intelligence (AI) technology which can accurately predict the risk of a heart attack, heart failure or cardiac death from routine cardiac CT scans, up to ten years in advance.